Reported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate

Benzinga

2026.11.06 06:01 (GMT+0)

Abrir en Benzinga